ProfileGDS5678 / 1423896_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 97% 96% 97% 97% 96% 97% 97% 97% 97% 97% 97% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.0472596
GSM967853U87-EV human glioblastoma xenograft - Control 29.3374297
GSM967854U87-EV human glioblastoma xenograft - Control 38.9664496
GSM967855U87-EV human glioblastoma xenograft - Control 49.6689597
GSM967856U87-EV human glioblastoma xenograft - Control 59.185697
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.8244396
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.8990297
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.3869997
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.282397
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.1789797
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.2078797
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.1463797
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.1795997
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0708897